Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Development Contract with Fortune 150 Company

11 May 2011 07:00

RNS Number : 2858G
Byotrol PLC
11 May 2011
 



 

11 May 2011

 

Byotrol plc

 

Global leader chooses Byotrol

for consumer products development contract

 

 

Byotrol plc ('Byotrol'), the developer of anti microbial hygiene technologies, is pleased to announce that it has agreed a significant joint development contract between a Fortune 150 company (the 'Partner') and its 50% owned subsidiary Byotrol Consumer Products Ltd ('BCP'). The goal of this agreement is to develop a range of products containing Byotrol's unique technology for global consumer markets.

 

Under the 9 month contract, BCP will receive between US$500,000 and US$1,000,000 in upfront, milestone-based payments, and offsets. The agreement entitles the Partner to exclusivities in certain global consumer markets and product forms, whilst providing funding for BCP's product development activities. Both parties will commit technical, testing, market insight and customer testing resources to the project.

 

On 21 December 2009 it was first announced that the two companies had entered into an option agreement, and in the intervening period they have been working jointly to evaluate the technology.

 

This contract is complementary to other development and distribution contracts recently announced by Byotrol, including the Robert McBride Group, P Z Cussons, and Tommee Tippee with Mayborn. 

 

Commenting on the contract, Gary Millar, CEO of Byotrol, said:

 

"This contract is a landmark deal for the business both in terms of its commercial potential and the collaborative nature of the joint development agreement. 

 

"Our strategy recognises that the full potential for Byotrol will be best achieved by working closely in partnership with leading companies and this agreement is an important step towards bringing Byotrol to consumers globally.

"I am very pleased to add that negotiations in reaching this agreement have been extremely positive; our partners in this have made a significant commitment of capital, management time and resource in developing Byotrol based products under their brand label. This demonstrates considerable faith in Byotrol and its technology by a successful multinational corporation and is a further endorsement of the potential for Byotrol."

 

 

Enquiries:

 

Byotrol plc 0161 277 9518

Gary Millar, Chief Executive

Richard Bell, Finance Director

 

Arbuthnot Securities 020 7012 2000

Nominated Adviser and broker

Antonio Bossi / Henry Willcocks

 

Winningtons 020 3176 4722

Tom Cooper / Paul Vann 0797 122 1972

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, microbacteria and algae.

 

The Byotrol product can be used as a standalone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTGCGDUSUBBGBG
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.